Showing results (101-110 of 167) with videos related to
Sort By:
Pageof 17
Drug Discovery Today|December 13, 2025
Genetic Targets, Financial Creativity: BridgeBio's Model for Sustainable Drug DevelopmentChinmay Shukla, Irwin Tendler, Neil Kumar, et al.Nucleic Acids Research|December 17, 2019
Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomesXue-Hai Liang, Hong Sun, Chih-Wei Hsu, et al.Nucleic Acid Therapeutics|December 21, 2018
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer ExperienceStanley T Crooke, Brenda F Baker, Shuting Xia, et al.Science Translational Medicine|June 20, 2014
Parallel discovery of Alzheimer's therapeuticsAndrew W Lo, Carole Ho, Jayna Cummings, et al.The Journal of Biological Chemistry|June 19, 2004
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysisWalt F Lima, Josh G Nichols, Hongjiang Wu, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 26, 2022
Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspectiveQingyang Xu, Joonhyuk Cho, Zied Ben Chaouch, et al.Contemporary Clinical Trials Communications|April 18, 2025
Predicting clinical trial duration via statistical and machine learning modelsJoonhyuk Cho, Qingyang Xu, Chi Heem Wong, et al.Drug Discovery Today|May 1, 2017
Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of MedicineEsther S Kim, Paige M C Omura, Andrew W LoJAMA Oncology|June 4, 2018
New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A ReviewSonya Das, Raphaël Rousseau, Peter C Adamson, et al.Molecular Pharmacology|October 10, 2006
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrateWalt F Lima, John B Rose, Josh G Nichols, et al.Pageof 17